pipeline-prospector-insert-v1
X

Find Drugs for Infections and Infectious Diseases in Phase I/ Phase II Clinical Development in UNITED STATES

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AP-PA02

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Innoviva

            Deal Size: $25.0 million Upfront Cash: Undisclosed

            Deal Type: Investment January 28, 2020

            Details:

            Armata to use the proceeds to support the ongoing advancement of its bacteriophage development programs, including the expected first in human studies related to Armata's lead phage candidate.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ribaxamase

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase I/ Phase II Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 07, 2020

            Details:

            The phase 1b/2a study will comprise a single center, randomized, double-blinded, placebo-controlled clinical trial of oral SYN-004 (ribaxamase) in up to 36 evaluable adult allogeneic HCT recipients.